CN1292659C - Biological disinfectant - Google Patents
Biological disinfectant Download PDFInfo
- Publication number
- CN1292659C CN1292659C CNB200410022896XA CN200410022896A CN1292659C CN 1292659 C CN1292659 C CN 1292659C CN B200410022896X A CNB200410022896X A CN B200410022896XA CN 200410022896 A CN200410022896 A CN 200410022896A CN 1292659 C CN1292659 C CN 1292659C
- Authority
- CN
- China
- Prior art keywords
- lactoferrin
- disinfectant
- chlorhexidine
- present
- distilled water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000645 desinfectant Substances 0.000 title claims abstract description 15
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 24
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 24
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 24
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 24
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 24
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 229960003260 chlorhexidine Drugs 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 2
- 230000003377 anti-microbal effect Effects 0.000 abstract 1
- 230000009982 effect on human Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000002070 Transferrins Human genes 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001502500 Trichomonadida Species 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a biological disinfectant which is characterized in that the present invention is prepared from the raw materials according to the following weight percentage by the method, wherein the raw materials comprise 0.1 to 1% of lactoferrin and 0.001 to 0.01% of chlorhexidine, and the rest is distilled water; the preparation method comprises the steps: the 0.1 to 1% of lactoferrin is dissolved in the distilled water; in addition, the 0.001 to 0.01% of chlorhexidine is dissolved in the distilled water; thus, the disinfectant is obtained by mixing the two liquids. In the present invention, because the lactoferrin which is biological engineering product is added, the thickness of the chlorhexidine is greatly reduced; thus, the side effect on human body skins is reduced; antimicrobic effect is improved because of the synergistic effect from the lactoferrin and chlorhexidine.
Description
Technical field:
The present invention relates to a kind of disinfectant, be specifically related to a kind of disinfectant and preparation method who contains biological products.
Background technology:
At present, be used for that the disinfectant of human body skin or mucous membrane is most to be synthetic, for example quaternary amine, chloride goods, this class disinfectant toxic and side effect is big, in the kill harmful microorganism, also can cause certain injury to human body skin, big for environment pollution in addition.
Summary of the invention:
Technical problem to be solved by this invention is the defective that overcomes above-mentioned prior art, and a kind of Disinfection Effect is good, nontoxic to human body skin, have no side effect biotype disinfectant and preparation method are provided.
The present invention solves the problems of the technologies described above by following technical scheme.It is characterized in that it is to constitute with following weight percentages: lactoferrin is 0.1%～1%, and hibitane is 0.001%～0.01%, and all the other are distilled water; Its preparation method is: get 0.1%～1% lactoferrin, and the adding distil water dissolving, other gets 0.001%～0.01% hibitane, the adding distil water dissolving, two liquid mix promptly.
The present invention passes through to add the Bio-engineering Products lactoferrin, thereby the concentration of hibitane is descended greatly, has reduced the side effect to human body skin, and because the synergy of hibitane and lactoferrin, antimicrobial effect is strengthened greatly.
Embodiment:
At present, along with the develop rapidly of biotechnology, have that various biological products are manufactured to come out.The Bio-engineering Products lactoferrin is the important component in the human milk, be that molecular weight is the glycoprotein of 78 kilodaltons, it is a member in the transferrins family, other member who belongs to transferrins has structural homology highly, the monomer glycoprotein that all has an about 80kD of big molecular group is made up of in conjunction with leaf (or zone) the iron of two repetitions.Although yet their structure is closely similar, lactoferrin demonstrates stronger IBC, particularly lactoferrin can keep iron in a wider pH scope and the performance combination stability that taps a blast furnace, and this is the key property of lactoferrin iron in conjunction with function.
Because the unique texture of lactoferrin, thus show antibacterial action, and can prophylaxis of microbial infect.Lactoferrin has three kinds of different mechanism of action to bacterium, and the first, the bacteriostasis of lactoferrin, this height iron binding affinity with it is relevant, and it can make bacterium lose the basic nutrient iron of required growth, stops biomembranous formation; The second, the bactericidal action of lactoferrin, it directly plays bactericidal action by lactoferrin N-terminal strong cation sterilization zone; The 3rd, lactoferrin can also be replied and brings into play antimicrobial acivity except being had antibacterial and bactericidal action by regulating general immunity.
In addition, because lactoferrin is to the high-affinity of iron, thereby make the living environment iron deficiency of bacterium, bacterium enters the environment that a kind of mobile status (this state can make them seek environment preferably) is replied certain nutritional deficiency by conversion, the immune defense that when bacterium is moved, is vulnerable to the host attack and the attack of other material (as antimicrobial agents, disinfectants etc.), this is with other medicines synergistic effect basis to take place.
It is the biguanides disinfectant that hibitane has another name called chlorhexidine, is a kind of toxicity, the safe disinfection agent that corrosivity and excitant are all very low.Can be widely used in the sterilization of skin and mucosa, the surface of a wound and urinary organ.
The present invention is by the mechanism of action and the physio-biochemical characteristics of the above-mentioned two kinds of materials of research, a kind of biotype disinfectant has been proposed, described this biotype disinfectant comprises lactoferrin, two kinds of compositions of hibitane, wherein lactoferrin concentration is between 0.1%～1%, and it is to make by gene engineering, and hibitane concentration is between 0.001%～0.01%, far below 0.01%～0.1% concentration in the prior art, solvent is a distilled water, has further reduced the toxicity of its preparation, uses safer.
Its preparation method is: get 0.1%～1% lactoferrin, and the adding distil water dissolving, other gets 0.001%～0.01 hibitane, the adding distil water dissolving, two liquid mix promptly.
The present invention all has more powerful killing action to all kinds of pathogenic microorganisms such as bacterium, mould, trichomonad, conveyor screws.Results of pharmacodynamic test shows that effect of the present invention 2 minutes is respectively 99.96% and 99.94% to staphylococcus aureus, colibacillary killing rate; Effect of the present invention 5 minutes is 99.73% to the oidiomycetic killing rate of white.Toxicity test through every standard, comprise skin irritatin test (average integral=0.0), mucomembranous irritant test (stimulation index=0.0), marrow polychromatic erythrocyte micronucleus test (opinion) to the micronucleus effect, cumulative toxicity test (cumulative coefficient＞5*, annotate *: cumulative coefficient is big more, safety is high more, 5 is the peak of this test) or the like, every test index is all qualified.
Claims (2)
1, a kind of biotype disinfectant is characterized in that it is to constitute with following weight percentages:
Lactoferrin is 0.1%～1%, and hibitane is 0.001%～0.01%, and all the other are distilled water.
2, a kind of preparation method of biotype disinfectant is characterized in that: get 0.1%～1% lactoferrin, and the adding distil water dissolving, other gets 0.001%～0.01% hibitane, the adding distil water dissolving, two liquid mix promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410022896XA CN1292659C (en) | 2004-02-16 | 2004-02-16 | Biological disinfectant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410022896XA CN1292659C (en) | 2004-02-16 | 2004-02-16 | Biological disinfectant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1559218A CN1559218A (en) | 2005-01-05 |
| CN1292659C true CN1292659C (en) | 2007-01-03 |
Family
ID=34440998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410022896XA Expired - Fee Related CN1292659C (en) | 2004-02-16 | 2004-02-16 | Biological disinfectant |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1292659C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1130020A (en) * | 1995-09-05 | 1996-09-04 | 陕西咸阳达康消毒产品有限责任公司 | Sterilizing liquid |
| CN1265007A (en) * | 1998-05-28 | 2000-08-30 | 曼德勒转化有限公司 | Disinfectant compsn. |
-
2004
- 2004-02-16 CN CNB200410022896XA patent/CN1292659C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1130020A (en) * | 1995-09-05 | 1996-09-04 | 陕西咸阳达康消毒产品有限责任公司 | Sterilizing liquid |
| CN1265007A (en) * | 1998-05-28 | 2000-08-30 | 曼德勒转化有限公司 | Disinfectant compsn. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1559218A (en) | 2005-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Güzel-Seydim et al. | Efficacy of ozone to reduce bacterial populations in the presence of food components | |
| CN1374003A (en) | Biological fruit and vegetable preservative | |
| CN103271091B (en) | Plant bactericide containing milk protein composition | |
| CN107669619A (en) | A kind of disposable hand-wrist bones gel and preparation method thereof | |
| CN1918999A (en) | Preparation process of nano antibacterial agent | |
| CA2641491C (en) | Method of inhibiting the growth of microorganism in aqueous systems using a composition comprising lysozyme | |
| CN114983842B (en) | Compound anti-corrosion composition and preparation method and application thereof | |
| CN1292659C (en) | Biological disinfectant | |
| CN101568257A (en) | Antibacterial agent and bactericidal agent | |
| CN101779641A (en) | Alcohol-group leather sterilization mildewcide | |
| CN112400901B (en) | Bactericidal composition and application thereof | |
| CN1088557C (en) | Persistent disinfectant and preparation process thereof | |
| CN106380748A (en) | Antibacterial toy plastic and preparation method thereof | |
| CN111166763A (en) | Bactericidal bacteriostatic agent | |
| WO2019239419A1 (en) | Methanoic acid composition and it's uses thereof | |
| CN101590064A (en) | Aseptic skin sterilizing agent for external use | |
| CN101744007A (en) | Disinfectant | |
| Bouryabaf et al. | Biofilm removal and antimicrobial activities of agar hydrogel containing colloid nano-silver against Staphylococcus aureus and Salmonella typhimurium | |
| CN108904527A (en) | Composite skin sterilizing liquid composite and preparation method thereof | |
| CN1207967C (en) | Sterilizing liquid for dry washing hand | |
| JPH07101810A (en) | Sterilizing composition and soap containing the same | |
| CN107459729A (en) | A kind of antibacterial food level PVC sheet and preparation method thereof | |
| CN101028534A (en) | Antiseptics curing liquid for contact lens | |
| CN101028004A (en) | Nano-silver antibacterial powder | |
| CN113303329B (en) | Disinfectant containing o-phenylphenol, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070103 Termination date: 20160216 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |